INIBIO: "Botulinum Toxin INIBO Receives Marketing Approval in China"
Third NMPA-approved product developed by a Korean company
Local commercialization targeted for the first quarter of 2027
"Expand revenue base through global market entry"
INIBIO said on October 27 that INIBO, its independently developed botulinum toxin type A product, had received marketing approval from China's National Medical Products Administration (NMPA).
After submitting an investigational new drug (IND) application in China in January 2023, INIBIO completed the approval process in approximately three years and nine months, following local clinical trials and a review of its marketing application. With this approval, INIBO became the ninth botulinum toxin product to enter the Chinese market and the third developed by a Korean company.
Building on the approval, INIBIO plans to work with its local partner to establish product supply and distribution systems, with commercialization targeted for the first quarter of 2027. The company plans to target the market, focusing on major medical aesthetics institutions and leveraging its partner's expertise in the medical aesthetics business and network of medical institutions. INIBO's marketing approval process is also underway in Brazil.
The approval in China is also expected to provide a new growth driver for GC Wellbeing's medical aesthetics business. Since entering the botulinum toxin business through its acquisition of INIBIO last year, GC Wellbeing has expanded its product portfolio to include fillers and ECM skin boosters. The company plans to expand its global revenue base through INIBO's entry into overseas markets and strengthen synergies across its medical aesthetics business, which spans toxins, fillers, and skin boosters.
Hot Picks Today
"They're Coming After My Pension Too?" Public Unease Mounts... Spain Sees Mass Protest Over Reform Push
- "Where Do You Go Every Lunch Break?"... 'Time-Poor' Men in Their 40s: Where They Spend Their Money.
- "Targeted Cars Changing Lanes"... More Than 900 Insurance Fraudsters Steal 7.5 Billion Won
- "Naked Again?" Controversial Actress Crosses a Line... Slammed for Sexualizing 'Child Characters'
- "A Really Beautiful Butt"... How Did Nicki Minaj React to Trump's Unexpected Remark?
An INIBIO representative said, "NMPA approval marks an important turning point that will enable us to make a full-scale entry into China's rapidly growing botulinum toxin market. We will work closely with our local partner to ensure a smooth launch in the first quarter of 2027 and accelerate the expansion of our global business by entering key overseas markets, including Brazil, and building synergies with GC Wellbeing's medical aesthetics portfolio."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
